Alpega Group Showed Impressive Results In 2020
Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005665/en/
Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020. (Photo: Alpega Group)
Alpega’s business units had an outstanding performance last year. On one hand, their freight exchanges’ customer acquisitions strongly grew by 20% compared to the previous year and existing clients had a higher renewal rate. On the other hand Alpega TMS added 83 new customers and had a tremendous increase in usage of their smart booking solution.
Alpega’s CEO, Todd DeLaughter, commented on these results: “I’m very excited with Alpega’s excellent performance proving the value of our solutions and the commitment of our employees to relentlessly serve our customers”
Critical developments in Alpega Group’s businesses have made their solutions ideal for the supply chain disruptions the transport industry now faces. The following is a recap of recent changes and events at Alpega, all of which promise to have a ripple effect in the coming year.
Supporting the Transportation Industry During COVID-19
An important player in the pharma sector chose Alpega TMS to ensure enhanced visibility and supply chain optimization. They were very satisfied with the agility of the Alpega team to rapidly implement the solution to cope with their logistics challenges, critical to fighting COVID19.
With initiatives like free access to its various solutions, such as Teleroute freight exchange, spot and smart booking, Alpega Group has shown solidarity with the transport industry and continues to aid in its recovery.
New Partnerships and solutions
Alpega’s partnership ecosystem powers their TMS solution. In 2020 Alpega established key partnerships with industry leaders such as Xeneta, project44, Shippeo and FourKites. In 2021 these partnerships will boost supply chain transparency for Alpega’s existing and future clients.
A payment guarantee solution for carriers was launched by Teleroute freight exchange, a unique service that allows carriers to be protected against non-payment.
New Leaders for New Growth
Alpega Group strengthened its management team and welcomed new senior leaders in 2020, including Gwyn Clay as Chief Product Officer and Jörg Heinen as VP of IT.
About Alpega Group
Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.
Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.
These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs over 600 people with 31 different nationalities.
For more information, visit www.alpegagroup.com
Head of Brand
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microsoft Azure Customers Now Able to Acquire beqom with Existing Azure Credit14.4.2021 16:20:00 EEST | Press release
beqom, provider of cloud-based compensation management software, announced that Microsoft has designated beqom as an eligible “Microsoft Transact” application for customers of the Microsoft Azure cloud platform. This means that Azure customers can use their existing Azure budget commitment to fund the purchase of the beqom compensation management solution. “This presents a huge opportunity for Azure customers,” says Francois D’Haegeleer, beqom Head of Business Development. “As an eligible application, if you purchase beqom directly through the Azure Marketplace, Microsoft will contribute 100% of qualifying offer purchases towards your organization’s Azure consumption commitment at each invoice period, including software/IP costs. So you can get beqom’s world-class compensation management platform, used by Global 2000 companies around the world, for no additional budget outlay.” “Our enterprise customers want to streamline their software procurement process,” says Andrew Reid, Microsoft
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer14.4.2021 16:00:00 EEST | Press release
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies. Under the new agreement, joint research will continue for five additional years. “Our collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an import
University of Siena Researchers Demonstrate Rapid UV Disinfection of Operating Rooms Between Surgeries14.4.2021 15:00:00 EEST | Press release
UltraViolet Devices, Inc. (UVDI), a global leader in Ultraviolet Air and Surface disinfection, announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at the Society for Healthcare Epidemiology of America (SHEA) Spring Conference, taking place April 13-16, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005184/en/ In the University of Siena research, the UVDI-360 Room Sanitizer effectively inactivated germs in operating rooms in six minutes. (Photo: Business Wire) In the research, conducted by Dr. Gabriele Messina, Professor of Public Health, University of Siena at the Rugani Hospital Monteriggioni in Siena, the UVDI-360 Room Sanitizer achieved a greater than 97% germ reduction in operating rooms in only six minutes, with two three-minute disinfection cycles run on each side of the operating table. Testing the UVDI-360 R
Amylyx Pharmaceuticals Provides Global Regulatory Update on AMX0035 for ALS14.4.2021 15:00:00 EEST | Press release
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of ALS. The company intends to submit a Marketing Authorization Application (MAA) for AMX0035 to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) by the end of 2021. As previously reported, the company plans to submit a marketing application with Health Canada Q2 2021. The FDA has expressed an interest in seeing data from an additional placebo-controlled clinical trial prior to receiving a New Drug Application (NDA), the vehicle through which a pharmaceutical sponsor formally proposes that the FDA approve an investigational product. To fulfill the FDA’s request and to continue to build upon the growing body of evidence supporting AMX0035 for
Noxopharm Files Septic Shock Treatment Patent for Veyonda®14.4.2021 15:00:00 EEST | Press release
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses. Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock. Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response
HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools14.4.2021 13:00:00 EEST | Press release
HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/ HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of h
Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin14.4.2021 12:59:00 EEST | Press release
Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite with a total area of around 270 m² will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals and be operational from the first quarter of 2022. Together with a new U.S. based cGMP facility, Eckert & Ziegler will be able to provide radiopharmaceutical development services to companies looking for Europe, US and worldwide contract manufacturing. “We have decided to make this investment to meet the growing global demand for radiopharmaceutical services in both imaging and therapy products. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom